Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

C R Dunstan

Showing results (71-80 of 83) with videos related to

Pageof 9
Sort By:
The Quarterly Journal of Medicine|May 1, 1985
The pathogenesis of renal osteodystrophy: role of vitamin D, aluminium, parathyroid hormone, calcium and phosphorusC R Dunstan, E Hills, A W Norman, et al.
Mineral and Electrolyte Metabolism|January 1, 1985
Treatment of hemodialysis bone disease with 24,25-(OH)2D3 and 1,25-(OH)2D3 alone or in combinationC R Dunstan, E Hills, A W Norman, et al.
The Journal of Cell Biology|May 4, 1999
The ligand for osteoprotegerin (OPGL) directly activates mature osteoclastsT L Burgess, Y Qian, S Kaufman, et al.
The Journal of Experimental Medicine|August 22, 2000
Osteoprotegerin reverses osteoporosis by inhibiting endosteal osteoclasts and prevents vascular calcification by blocking a process resembling osteoclastogenesisH Min, S Morony, I Sarosi, et al.
Genes & Development|June 6, 1998
osteoprotegerin-deficient mice develop early onset osteoporosis and arterial calcificationN Bucay, I Sarosi, C R Dunstan, et al.
Arthritis and Rheumatism|June 1, 2006
The ratio of circulating osteoprotegerin to RANKL in early rheumatoid arthritis predicts later joint destructionP P Geusens, R B M Landewé, P Garnero, et al.
Blood|December 12, 2001
Osteoprotegerin inhibits the development of osteolytic bone disease in multiple myelomaP I Croucher, C M Shipman, J Lippitt, et al.
Nature|February 9, 1999
OPGL is a key regulator of osteoclastogenesis, lymphocyte development and lymph-node organogenesisY Y Kong, H Yoshida, I Sarosi, et al.
Proceedings of the National Academy of Sciences of the United States of America|March 31, 1999
Tumor necrosis factor receptor family member RANK mediates osteoclast differentiation and activation induced by osteoprotegerin ligandH Hsu, D L Lacey, C R Dunstan, et al.
Proceedings of the National Academy of Sciences of the United States of America|March 4, 2000
RANK is the intrinsic hematopoietic cell surface receptor that controls osteoclastogenesis and regulation of bone mass and calcium metabolismJ Li, I Sarosi, X Q Yan, et al.
Pageof 9

Showing results (71-80 of 83) with videos related to

Sort By:
Pageof 9
The Quarterly Journal of Medicine|May 1, 1985
The pathogenesis of renal osteodystrophy: role of vitamin D, aluminium, parathyroid hormone, calcium and phosphorusC R Dunstan, E Hills, A W Norman, et al.
Mineral and Electrolyte Metabolism|January 1, 1985
Treatment of hemodialysis bone disease with 24,25-(OH)2D3 and 1,25-(OH)2D3 alone or in combinationC R Dunstan, E Hills, A W Norman, et al.
The Journal of Cell Biology|May 4, 1999
The ligand for osteoprotegerin (OPGL) directly activates mature osteoclastsT L Burgess, Y Qian, S Kaufman, et al.
The Journal of Experimental Medicine|August 22, 2000
Osteoprotegerin reverses osteoporosis by inhibiting endosteal osteoclasts and prevents vascular calcification by blocking a process resembling osteoclastogenesisH Min, S Morony, I Sarosi, et al.
Genes & Development|June 6, 1998
osteoprotegerin-deficient mice develop early onset osteoporosis and arterial calcificationN Bucay, I Sarosi, C R Dunstan, et al.
Arthritis and Rheumatism|June 1, 2006
The ratio of circulating osteoprotegerin to RANKL in early rheumatoid arthritis predicts later joint destructionP P Geusens, R B M Landewé, P Garnero, et al.
Blood|December 12, 2001
Osteoprotegerin inhibits the development of osteolytic bone disease in multiple myelomaP I Croucher, C M Shipman, J Lippitt, et al.
Nature|February 9, 1999
OPGL is a key regulator of osteoclastogenesis, lymphocyte development and lymph-node organogenesisY Y Kong, H Yoshida, I Sarosi, et al.
Proceedings of the National Academy of Sciences of the United States of America|March 31, 1999
Tumor necrosis factor receptor family member RANK mediates osteoclast differentiation and activation induced by osteoprotegerin ligandH Hsu, D L Lacey, C R Dunstan, et al.
Proceedings of the National Academy of Sciences of the United States of America|March 4, 2000
RANK is the intrinsic hematopoietic cell surface receptor that controls osteoclastogenesis and regulation of bone mass and calcium metabolismJ Li, I Sarosi, X Q Yan, et al.
Pageof 9